undamentalytics Newsletter
Sign in

Travere Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Travere Therapeutics, Inc. had total assets of $605m, total liabilities of $490m and shareholders' equity of $115m. It held $93.0m in cash against $312m of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Feb 20112012Feb 20122016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents——4199103628516662585993124
Receivables——19141318161617212780108
Inventory——35668759423644
Total current assets—0332326496429410583486617417438633
Goodwill——111111111——
Total assets—0525520709605607777673789594605848
Accounts payable——81972712151742242515
Deferred revenue (current)——————0161273——
Total current liabilities—083861059593124142178201160211
Total debt——4445218205215227376377379312—
Total liabilities——218227391384396475630588535490826
Shareholders' equity0−0308293318221211302432015911523
Shares outstanding——38m39m41m43m52m62m64m75m87m91m96m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: EBS vs TVTXALVO vs TVTXAMPH vs TVTXPCRX vs TVTX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Travere Therapeutics, Inc.